Use of filgrastim in patients undergoing cytotoxic chemotherapy leads to significant reductions in the incidence, severity and duration of neutropenia and febrile neutropenia.
Tsütotoksilist kemoteraapiat saavate patsientide ravi filgrastiimiga vähendab oluliselt neutropeenia ja febriilse neutropeenia esinemissagedust ja raskusastet ning lühendab selle kestust.